How much do you know about the incidence and screening of prostate cancer? Here's your chance to find out.
A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.
Prostate cancer is the most frequent cancer found in American men, and the second leading cause of cancer death in this population. Currently, scores of reputable clinical trials are underway and recruiting patients.
Researchers looked at data from the Surveillance, Epidemiology, and End Results database to see if there has been any increase in the use of active surveillance or watchful waiting when it comes to low-risk prostate cancer.
The study compared PET/CT tracers over 18F-fluciclovine when it comes to the localization of biochemical recurrence of prostate cancer following radical prostatectomy.
Test your knowledge of metastatic prostate cancer with this month's quiz.
Researchers conducted gene expression analyses on prostate cancer tumor samples from World Trade Center first responders and general population patients to see if there were any differences between the two.
Dr. Kittles discusses the race-based health disparities in prostate cancer, and one genetic-environmental crossover that is clinically significant.
How much do you know about molecular risk and prognostic biomarkers in prostate cancer? Take our latest quiz to test your knowledge.
A new study used two patient-reported measures of sexual function following radical prostatectomy to assess sexual interest and satisfaction in men with prostate cancer.